Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder

Next Previous
Search
Trial Profile

A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aripiprazole (Primary) ; Aripiprazole/escitalopram (Primary) ; Escitalopram (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms ACES 263

    • Most Recent Events

    • 05 Apr 2022 This trial has been completed in France (End Date: 1 Sep 2011) according to European Clinical Trials Database record.
    • 12 Oct 2013 Planned number of patients changed from 1200 to 1500 as reported by European Clinical Trials Database.
    • 13 Mar 2012 Actual patient number added 45 according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top